敷胸散辅助治疗儿童肺炎支原体肺炎的多中心临床研究

doi:10.20274/j.cnki.issn.1674-3865.2025.02.001

Chinese Pediatrics of Integrated Traditional and Western Medicine ›› 2025, Vol. 17 ›› Issue (2): 93-98.doi: 10.20274/j.cnki.issn.1674-3865.2025.02.001

A multi center clinical study on the adjuvant treatment with Fuxiong powder for children with Mycoplasma pneumoniae pneumonia

SHEN Hongyan¹，ZHANG Xiuying¹，TAN Chunying²，SHANG Tao³，MENG Bin⁴，MU Jingwen⁵，TIAN Zhifan⁵，E Mingxin⁵，WANG Xuefeng¹

¹Affiliated Hospital of Liaoning University of Traditional Chinese Medicine，Shenyang 110032，China;
²Liaoning Provincial Maternal and Child Health Hospital，Shenyang 110005，China;³Kaiyuan Hospital of Traditional Chinese Medicine，Kaiyuan 112399,China;4Benxi Manchu Autonomous County Hospital of Traditional Chinese Medicine,Benxi 117110,China;5Liaoning University of Traditional Chinese Medicine,Shenyang 110847，China

Received:2025-02-10 Published:2025-04-25 Online:2025-04-25
Contact: WANG Xuefeng，E-mail：lnzywxf@163.com

Abstract

Abstract: Objective:To evaluate the clinical efficacy and safety of Fuxiong powder in the adjuvant treatment of Mycoplasma pneumoniae pneumonia（phlegm-heat closing lung syndrome） in children.Methods:Totally 120 children with Mycoplasma pneumoniae pneumonia（phlegm-heat closing lung syndrome） were selected as the study subjects,who were admitted to the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine，Liaoning Provincial Maternal and Child Health Hospital，Benxi Manchu Autonomous County Hospital of Traditional Chinese Medicine and Kaiyuan Hospital of Traditional Chinese Medicine from October 2024 to January 2025，and they were divided into two groups according to their wishes:60 cases in the experimental group and 60 cases in the control group.The control group was treated with basic treatment with western medicine，and the experimental group was treated with Fuxiong powder in addition to the basic treatment with western medicine.The course of treatment was 7 d.The clinical efficacy，time to remission of main symptoms，disappearance time of pulmonary signs（rales），TCM syndrome scores and adverse reactions were compared between the two groups.Results:After treatment，the healing and improvement rate of experimental group was 72%-22% (39/54),and the total effective rate was 92%-59% (50/54),both of which were higher than the control group ［(50%-91%,28/55）and (83%-64%,46/55)］,showing that the clinical efficacy of the experimental group was better than that of the control group (P<0.05).The relief time of clinical symptoms（cough，wheezing due to retention of phlegm in the throat，shortness of breath） and the disappearance time of pulmonary signs (rales) in the experimental group were both less than those in the control group (P<0.05).The TCM syndrome score was lower than before treatment in both groups，and the experimental group was better than the control group (P<0.05).There was no significant difference in the incidence of adverse events between the two groups（P>0.05）.Conclusion:The adjuvant treatment for Mycoplasma pneumoniae pneumonia（phlegm-heat closing lung syndrome） in children with Fuxiong powder has a good clinical efficacy，which can effectively promote rales absorption and improve the symptoms of cough,wheezing due to retention of phlegm in the throat and shortness of breath，and is safe.

Key words: Mycoplasma pneumoniae pneumonia, Traditional Chinese medicine external treatment method, Fuxiong powder, Child

SHEN Hongyan, ZHANG Xiuying, TAN Chunying, SHANG Tao, MENG Bin, MU Jingwen, TIAN Zhifan, E Mingxin, WANG Xuefeng. A multi center clinical study on the adjuvant treatment with Fuxiong powder for children with Mycoplasma pneumoniae pneumonia[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 93-98.

[1]	WU Pan, HUANG Tingyue, ZHANG Zhanling, WANG Xuefeng. Meta analysis and GRADE evaluation of Xiaoer Feire Kechuan oral liquid in the treatment of Mycoplasma pneumoniae pneumonia [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 98-108.
[2]	LI Jianying, XUE Lingyan, HE Chunlan, ZHAO Lingli. Effects of human milk oligosaccharides in breast milk on intestinal flora of infants and research progress [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 121-125.
[3]	YAN Fuli, GAO Jing. Research progress in cell derived exosomes carrying different miRNAs in hypoxic ischemic encephalopathy models [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 126-.
[4]	JIANG Ling, ZHANG Di, LlU Ying. Research progress of neurotransmitter imbalance in tic disorders [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 132-.
[5]	LI Ruixue, WANG Xuefeng, CAI Zhuang. Application analysis of Professor Wang Xuefeng′s treatment for hysterical attack syndrome characterized by dyspnea based on the theory of "wood fire tormenting metal" [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 137-.
[6]	LI Ying, DONG Hanyu, DONG Dan, WANG Xuefeng. Experience in treating short stature in children based on spleen with Sijunzi decoction as the core formula [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 150-.
[7]	YANG Yang, CHEN Zhu, CHEN Na, XIAO Ping, LOU Hui, LENG Jiahui. Analysis of the formulae for the treatment of precocious puberty in girls with Erdi Yishu soup [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 154-.
[8]	XIN Xiaohui, LI Min, WANG Yajing, LI Fajun, QIU Xiaojin. Characteristics of TCM constitution distribution in 1 479 children aged 3 to 14 in urban and suburban areas of Beijing [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(2): 173-.
[9]	KONG Xinyue, WANG Xuefeng, WANG Yulin. Analysis of the distribution of traditional Chinese medicine constitution and susceptible risk factors of severe Mycoplasma pneumoniae pneumonia in children [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2024, 16(6): 495-499.
[10]	QU Shengyue, MU Jingwen, YANG Jianshu, ZHAO Hangyu, ZHANG Xiuying, WANG Xuefeng. Clinical efficacy observation of Xiaoer Kechuanling oral solution (concentrated) in the treatment of Mycoplasma pneumoniae pneumonia in children [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2024, 16(5): 431-435.
[11]	ZHANG Songlin, GUO Yanjun, FENG Risheng. Significances of detection of T cell subsets，IgE and RANTES in infants with refractory Mycoplasma pneumoniae pneumonia [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2023, 15(3): 229-232.
[12]	SU Yonghong, SUN Xueli, YANG Lili, YAN Wenjuan, WU Chunlian. Risk factors of myocardial damage in children with Mycoplasma pneumoniae pneumonia [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2022, 14(4): 323-325.
[13]	LIAN Chaoyu, XU Guangming, YAN Yanjie, YANG Junge. Relationship between disease severity and levels of vitamin D,C-reactive protein and D-dimer in children with Mycoplasma pneumoniae pneumonia [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2022, 14(3): 225-228.
[14]	YAN Qiuli, HAO Chuangli. Clinical study of bronchoscopy intervention at different time points for children with refractory Mycoplasma pneumoniae pneumonia [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2022, 14(2): 138-141.
[15]	YUAN Xiaoxu, JIA Chunmei. The clinical significance of D-dimer level in children with severe Mycoplasma pneumoniae pneumonia [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2022, 14(1): 29-32.

A multi center clinical study on the adjuvant treatment with Fuxiong powder for children with Mycoplasma pneumoniae pneumonia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments